Drug Search Results
More Filters [+]

APL-5125

Alternative Names: APL-5125, APL 5125, APL5125
Latest Update: 2024-07-09
Latest Update Note: Clinical Trial Update

Product Description

Novel small molecule kinase inhibitor that blocks tumorigenic wnt signalling. (Sourced from: https://www.apollotx.com/pipeline/)

Mechanisms of Action: Wnt Blocker

Novel Mechanism: Yes

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Apollo Therapeutics Ltd
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for APL-5125

Countries in Clinic: United States

Active Clinical Trial Count: 1

Highest Development Phases

Phase 2: Adenocarcinoma|Appendiceal Cancer|Cholangiocarcinoma|Colorectal Cancer|Endometrial Cancer|Gastrointestinal Cancer|Ovarian Cancer|Pancreatic Cancer|Prostate Cancer|Triple Negative Breast Cancer

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

AP10CP01

P2

Recruiting

Gastrointestinal Cancer|Colorectal Cancer|Pancreatic Cancer|Adenocarcinoma|Triple Negative Breast Cancer|Ovarian Cancer|Appendiceal Cancer|Cholangiocarcinoma|Prostate Cancer|Endometrial Cancer

2027-04-01

Recent News Events

Date

Type

Title